Moderna, INC

Moderna reported Q2 2026 results with flat revenue of $145 million, a GAAP net loss of $0.8 billion, and improved operating expense outlook for the year.

Moderna, Inc. announced the appointment of Michael McDonnell, former CFO of Biogen, to its Board of Directors, effective July 8, 2026, to bolster financial leadership.

Moderna, Inc. announced amendments to its bylaws establishing federal district courts as the exclusive forum for securities-related lawsuits and reported results from its 2026 Annual Meeting of Stockholders.

Moderna reported fourth quarter and full-year 2025 financial results, including significant net losses, while outlining 2026 revenue growth targets and key pipeline advancements despite regulatory setbacks for its flu vaccine.

Moderna announced preliminary 2025 financial results exceeding prior guidance and outlined a strategic focus on seasonal vaccines and pipeline advancements for 2026.

Moderna reports strong operational execution and pipeline progress in 2025 despite a difficult U.S. environment, projecting up to 10% revenue growth in 2026.

Moderna reported Q2 2026 results with total revenue increasing to $145 million, driven by other revenue, while net loss slightly narrowed to $782 million.

Moderna reports a $1.34 billion net loss for Q1 2026, driven by a $950 million litigation settlement with Arbutus and Genevant.

Moderna reported a significant revenue decline and net loss in Q3 2025, driven by lower COVID vaccine sales, while advancing its pipeline with new approvals and discontinuations.

Moderna, Inc. reported a significant decrease in net product sales and total revenue for the second quarter and first half of 2025, while simultaneously advancing its respiratory virus vaccine portfolio with new FDA approvals and positive clinical trial results for its seasonal flu vaccine.

Moderna's Q1 2025 revenue decreased due to lower COVID vaccine sales, reflecting the shift to a seasonal respiratory vaccine market, while the company progresses its pipeline and manages costs.

Moderna's Q3 2024 results show stable revenue with significant improvements in profitability due to cost optimization efforts, despite a net loss for the nine-month period.

Moderna's 2024 10-K filing highlights a year of transition, marked by commercial challenges, strategic portfolio prioritization, and advancements in its mRNA platform and pipeline.

Moderna's 2023 annual report highlights a shift to an endemic COVID-19 vaccine market, significant manufacturing resizing, and advancements in its diverse mRNA pipeline.

Stephen Hoge, President of Moderna, Inc., sold 53,336 shares of common stock on July 15, 2026 for $67.60 per share.

Moderna Director Michael R. McDonnell reports acquisition of stock options and restricted stock units, with vesting schedules outlined.

Moderna's Chief Commercial Officer, Banque Soria Ester, reported transactions involving stock options and restricted stock units.

Moderna's Chief Financial Officer, James M. Mock, has reported transactions involving restricted stock units and common stock.

Moderna President Stephen Hoge reported transactions involving company stock, including purchases and sales, executed under a Rule 10b5-1 trading plan.

Moderna's Chief Legal Officer, Shannon Klinger, engaged in a series of stock transactions, including purchases and sales, under a Rule 10b5-1 trading plan.

Moderna, Inc. has filed its definitive proxy statement with the SEC, an administrative step for shareholder meetings.

Moderna is seeking shareholder approval for a one-time stock option exchange program designed to retain non-Executive Committee employees by addressing significantly underwater stock options.

Moderna Inc. has filed definitive additional proxy soliciting materials with the Securities and Exchange Commission.

Moderna's 2025 proxy statement outlines key proposals for the annual shareholder meeting, including the election of directors, an advisory vote on executive compensation, and the ratification of the company's independent auditor.

Moderna, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to its upcoming shareholder meeting.

Moderna's proxy statement outlines proposals for the upcoming annual meeting, including director elections, executive compensation, and amendments to the company's certificate of incorporation.

Baillie Gifford & Co has updated its Schedule 13G filing, reporting beneficial ownership of 18,206,778 shares of Moderna, Inc. common stock, representing 4.6% of the class.

Vanguard Capital Management has disclosed beneficial ownership of 25,933,824 shares, representing 6.53% of Moderna Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported zero beneficial ownership in Moderna Inc. common stock following an internal realignment effective January 12, 2026.

Baillie Gifford & Co. has filed an amendment to its Schedule 13G, reporting a 5.27% beneficial ownership stake in Moderna, Inc. as of December 31, 2025.

FMR LLC and its affiliates, including Abigail P. Johnson, reported beneficial ownership of 10.6% of Moderna Inc.'s common stock as of January 30, 2026.

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a 7.2% beneficial ownership stake in Moderna Inc. as of December 31, 2025.